Serogroup C <i>Neisseria meningitidis</i> invasive infection: analysis of the possible vaccination strategies for a mass campaign

Chiappini, Elena; Venturini, Elisabetta; Bonsignori, Francesca; Galli, Luisa; Martino, Maurizio de

doi:10.1111/j.1651-2227.2010.01908.x

Cited by 11 publications

(14 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 1999, an efficacious conjugate vaccine against MenC disease, consisting of serogroup C capsule polysaccharide conjugated to tetanus toxoid as carrier protein, has been licensed in Europe and has been used widely ever since. However, in the absence of randomised controlled trials on efficacy that support a specific vaccination schedule, each country has its own scheme with respect to the MenC conjugate vaccine (Table 1) [3]. In general, regardless of the vaccination schedule that has been followed, all countries that implemented the MenC conjugate vaccine in their programme experienced substantial declines in the incidence of MenC disease [4].…”

Section: Introductionmentioning

confidence: 99%

Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands

et al. 2012

View full text Add to dashboard Cite

BackgroundThe first meningococcal serogroup C (MenC) conjugate vaccine was licensed in 1999 and introduced in the United Kingdom. Countries that have implemented the MenC vaccine since then in their national immunisation programmes use different schedules. Nevertheless, all involved countries seem to experience substantial declines in the incidence of MenC disease.DiscussionSince 2001, the MenC conjugate vaccine has been implemented in the Netherlands by offering a single dose to all children aged 14 months. Prior to the introduction of the vaccine into the national immunisation programme, a catch-up vaccination campaign was initiated in which a single dose of the MenC conjugate vaccine was offered to all children aged from 14 months up to and including 18 years. Since then, there has been no report of any case of MenC disease among immunocompetent vaccinees. Administration of a single dose of MenC conjugate vaccine after infancy could be beneficial considering the already complex immunisation schedules with large numbers of vaccinations in the first year of life. The present paper deals with the advantages and critical aspects of a single dose of the MenC conjugate vaccine.SummaryA single dose of MenC conjugate vaccine at the age of 14 months in combination with a catch up vaccine campaign appeared to be a successful strategy to prevent MenC disease in the Netherlands, thereby confirming that a single dose of the vaccine could sufficiently protect against disease. Nevertheless, this approach can only be justified in countries with a relatively low incidence of serogroup C meningococcal disease in the first year of life. Furthermore, a good surveillance programme is recommended for timely detection of vaccine breakthroughs and outbreaks among non-vaccinees, since long-term protection after a single dose in the second year of life cannot currently be guaranteed.

show abstract

Section: Introductionmentioning

confidence: 99%

Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands

et al. 2012

View full text Add to dashboard Cite

show abstract

“…An increase, albeit much more marked, in the relative proportion and the absolute numbers of MenC IMD during the 1990s led to the development and routine use of conjugate vaccines. 10,33 In the UK, MenC vaccine coverage was greater than 80% and effectiveness ranged from 88 to 98% for various age groups in the first year of immunization. A rapid and substantial (93%) decline in MenC IMD cases was observed 34 and maintained because of the striking reduction in carriage, particularly of ST-11 hyperinvasive isolates that resulted from catch-up vaccination.…”

Section: Discussionmentioning

confidence: 99%

Increase of meningococcal serogroup Y cases in Europe: A reason for concern?

Bröker

Jacobsson

DeTora

et al. 2012

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Neisseria meningitidis is differentiated into 12 distinct serogroups of which A, B, C, W-135, X and Y are medically most important and represent a major health problem in one or more parts of the world. The epidemiology of N. meningitidis is unpredictable over time and across geographic regions. A sudden increase or decrease of IMD or meningococcal carriage may occur anywhere at any time. Recent epidemiological surveillance indicates an increase of serogroup Y IMD in some parts of Europe and data from various European countries are presented.

show abstract

“…Nei Paesi che hanno condotto una vaccinazione di massa contro il sierogruppo C con differenti schedule, si è assistito a una rilevante riduzione della malattia invasiva sostenuta da questo sierogruppo [35].…”

Section: Antimeningococcica: Situazione Attuale E Prospettive Futureunclassified

Meningococcal vaccine evolution

Bona

Guidi

2012

CMI

View full text Add to dashboard Cite

Serogroup C Neisseria meningitidis invasive infection: analysis of the possible vaccination strategies for a mass campaign

Abstract: While waiting for the introduction of other antimeningococcal vaccines, covering also for the Group B meningococci, further studies on effectiveness of an optimal schedule to be adopted in European countries are needed.

Cited by 11 publications

References 50 publications

Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands

Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands

Increase of meningococcal serogroup Y cases in Europe: A reason for concern?

Meningococcal vaccine evolution

Contact Info

Product

Resources

About